Given that phlorizin is a competitive inhibitor of SGLT1 and SGLT2, researchers have developed a highly selective inhibitor of SGLT2 empagliflozin for the treatment of type 2 diabetes. This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.